Journal
JOURNAL OF POSTGRADUATE MEDICINE
Volume 58, Issue 4, Pages 275-285Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0022-3859.105448
Keywords
Apixaban; dabigatran; novel anticoagulants; rivaroxaban
Categories
Ask authors/readers for more resources
Well-documented drawbacks of traditional anticoagulants have lead to the quest for an ideal anticoagulant resulting in a surge of novel anticoagulant molecules. These newer agents directly target specific steps in coagulation cascade and include newer low molecular weight heparins (adomiparin), ultra low molecular weight heparins (semuloparin, RO-14), inhibitors of activated factor II (dabigatran, AZD0837), X (rivaroxaban, apixaban, edoxaban, betrixaban), IX (REG1,2), XI (antisense oligonucleotides, BMS 262084, clavatadine A), VII/tissue factor (tifacogin, PCI 274836, and BMS 593214), V (recomodulin, solulin), VIII (TB402), dual thrombin/factor X inhibitors (EP21709, tanogitran), and newer vitamin K antagonists (tecarfarin). Direct thrombin inhibitors and Factor X inhibitors are the most clinically advanced. This article discusses the recent advances in the development of novel targets of anticoagulants. Medline, EMBASE, cochrane database, medscape, SCOPUS, and clinicaltrials.gov were searched using terms anticoagulants, blood coagulation inhibitors, anticoagulants and venous thromboembolism, anticoagulants and atrial fibrillation, and `antithrombins. Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were screened.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available